anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Torsades de pointes and ventricular tachycardia have been reported with anagrelide. Obtain a pre-treatment cardiovascular examination including an ECG in all patients. During treatment with anagrelide monitor patients for cardiovascular effects and evaluate as necessary.

Anagrelide increases the QTc interval of the electrocardiogram and increases the heart rate in healthy volunteers [ see Clinical Pharmacology (12.2)]. 

Do not use anagrelide in patients with known risk factors for QT interval prolongation, such as congenital long QT syndrome, a known history of acquired QTc prolongation, medicinal products that can prolong QTc interval and hypokalemia [see Drug Interactions (7.1)]. 

Hepatic impairment increases anagrelide exposure and could increase the risk of QTc prolongation. Monitor patients with hepatic impairment for QTc prolongation and other cardiovascular adverse reactions. The potential risks and benefits of anagrelide therapy in a patient with mild and moderate hepatic impairment should be assessed before treatment is commenced. Reduce anagrelide dose in patients with moderate hepatic impairment. Avoid use of anagrelide in patients with severe hepatic impairment.

In patients with heart failure, bradyarrhythmias, or electrolyte abnormalities, consider periodic monitoring with electrocardiograms [see Clinical Pharmacology (12.2)]. 

Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor and may cause vasodilation, tachycardia, palpitations, and congestive heart failure. Other drugs that inhibit PDE3 have caused decreased survival when compared with placebo in patients with Class III-IV congestive heart failure [see Drug Interactions (7.2)]. 

In patients with cardiac disease, use anagrelide only when the benefits outweigh the risks.
Elevated rates for depression in diabetic patients are of clinical significance for diabetology. Depressive disorders are doubled compared to patients without diabetes. A meta-analysis showed that a proportion of 20% of diabetic patients showed subthreshold depression, defined as elevated depressive symptoms without meeting criteria for clinical depression. Depression in diabetes is associated with a reduced quality of life, more diabetes related distress, and higher health related costs. But besides this, depression in diabetes seems to be an independent negative prognostic factor for morbidity and mortality. Furthermore subthreshold depression is a major barrier of an effective self-management of the disease.

Until now antidepressive therapies are only evaluated in clinically depressed diabetic patients. For the majority of depressed diabetic patients suffering from subthreshold depression no evaluated specific intervention concept exists. Since subthreshold depression often is associated with diabetes related distress a diabetes specific intervention was developed to support patients to increase their problem solving skills, modify their depressive cognitions and improve their coping with diabetes related distress. It consists of five sessions and is delivered as a group intervention.

This study is an efficacy trial. In this randomized trial the efficacy of this newly developed intervention is compared to a control condition consisting of five standard diabetes education lessons. The primary outcome variable is the reduction of depressive symptoms twelve months after the intervention. Secondary outcome variables are the quality of life, metabolic parameters, self-care behavior and other psychosocial aspects. Furthermore the possible covariation between change of depressive symptoms and inflammatory and immune markers will be analyzed.
Take 5 tablets of the control drug (placebo) each time, 3 times a day, 4.5g a day. Take it with warm water half an hour before meals.
The invention relates to anti-AIDS (acquired immune deficiency syndrome) five-in-one nano-TCM (traditional Chinese medicine) and a production method thereof. The materials of the anti-AIDS five-in-one nano-TCM comprise the following effective components by weight ratio: 25 to 50 parts of mongolian snakegourd root, 15 to 30 parts of glycyrrhiza, 30 to 60 parts of giant knot weed, 30 to 60 parts of monkshood and 30 to 60 parts of fructus forsythia. The production process comprises the following steps: crushing for pre-processing; crushing, extracting and dispersing on a high-frequency ultrasonic basis; extracting on a microwave basis; spraying, drying and crushing on a supersonic basis; nano-grinding; mixing; capsule-filling; and sterilizing. The formula of the anti-AIDS five-in-one nano-TCM achieves the curative effects of tonifying the vigor, strengthening the promordial energy, eliminating the stagnation, eliminating the dampness, clearing the heat, eliminating the toxins, and resisting the virus and tumour and has no toxicity or side effects. Therefore, the anti-AIDS five-in-one nano-TCM is suitable for treating patients infected with HIV and other viruses. The anti-AIDS five-in-one nano-TCM based on the formula is administered at four times each day according to the 'midnight-noon ebb-flow' theory and the circulation pattern of human vigor and blood through the syndrome differentiation and treatment, efficacy analysis, body resistance strengthening, pathogenic factor elimination, monarch, minister, assistant and guide theory and reasonable compatibility; and the anti-AIDS five-in-one nano-TCM is applied to the local skin of the human body at different time for treatment through acupoint drug administration and percutaneous absorption.
PURPOSE:To stabilize a specific benzimidazole compound by adding aluminum glycinate and a buffering agent as stabilizers to the benzimidazole compound, the benzimidazole compound having an excellent gastric acid secretion-inhibiting activity and an excellent antiulcer activity, being low toxic and being unstable against acids. CONSTITUTION:A 2-[(2-pyridyl) methylsulfinyl] benzimidazole compound having an excellent antiulcer activity and unstable against acids is compounded with aluminum glycinate and a buffering agent (preferably disodium hydrogenphosphate) as stabilizers for the stabilization of the compound. The aluminum glycinate and the buffering agent are desirably compounded in amounts of 0.1-20 pts.wt. and 0.01-20 pts.wt., respectively, per pt.wt. of the benzimidazole compound. The preparation is a little in the change of the appearance even when stored for a long period, does substantially not cause the lowering of the content of the ingredient and exhibits excellent stability. The preparation is especially effective for treating gastrointestinal ulcer, etc.
The plan is to have 50 people take part in this study at Mayo Clinic Rochester. This research study is looking at people who have a new condition called erosive reflux esophagitis. Esophagitis is defined as mucosal damage produced by the abnormal reflux of gastric contents into the esophagus. Acid reflux, over time, can wear away or erode the lining of your esophagus. This condition is called erosive esophagitis. The treating physician may start you on prescription strength acid reducing group of medications called Proton Pump Inhibitors (PPI). PPI medications can provide 24-hour relief from your painful heartburn symptoms and it can help you heal the erosions in the esophagus that acid reflux may cause.
Mitigating inflammation associated with the foreign body response (FBR) remains a significant challenge in enhancing the performance of implantable medical devices. Current anti-inflammatory approaches aim to suppress implant fibrosis, the major outcome of the FBR, but also inadvertently inhibit beneficial immune signalling necessary for tissue healing and vascularization. In a previous study, we demonstrated the feasibility of 'selective' immunosuppression targeting the NLRP3 inflammasome using the small molecule inhibitor MCC950, leading to reduced implant fibrosis without compromising healing and leading to enhanced vascularization. However, the clinical potential of MCC950 is severely limited due to its failure to pass Phase I clinical safety trials. This has triggered substantial efforts to develop safer analogues of NLRP3 inhibitors. Dapansutrile (OLT1177) is emerging as a leading candidate amongst current NLRP3 inhibitors, demonstrating both safety and effectiveness in a growing number of clinical indications and Phase 2 trials. While the anti-inflammatory effects of OLT1177 have been shown, validation of these effects in the context of implanted materials and the FBR have not yet been demonstrated. In this study, we show OLT1177 possesses beneficial effects on key cell types which drive FBR outcomes, including macrophages, fibroblasts, and smooth muscle cells. Evaluation of OLT1177 in a 28 day subcutaneous implantation model showed OLT1177 reduced fibrotic capsule formation while promoting implant vascularization. Mechanistic studies revealed that this occurred through activation of early pro-angiogenic markers while suppressing late-stage anti-angiogenic markers. These findings establish OLT1177 as a promising therapeutic approach for mitigating implant fibrosis while supporting vascularisation, suggesting a highly promising selective immunosuppressive strategy for the FBR warranting further research to explore its optimal integration into medical materials and devices.
Immediately after the sleep hygiene content, the overview of the mindfulness intervention will be offered. All enrolled participants in Arm A, Study Period 1, will attend a 15 minute in-person "Introduction to Mindfulness" session after randomization.
A method of reducing the appearance of loose, sagging, or flaccid skin is disclosed. The method can include topically applying to skin in need thereof a composition that includes 0.0001 wt. % to 10 wt. %  Argania spinosa  kernel extract, 0.0001 wt. % to 10 wt. % dill extract, 0.0001 wt. % to 10 wt. %  Myrciaria dubia  fruit extract, and 0.0001 wt. % to 10 wt. %  Croton lechleri  extract or  Morus alba  fruit extract. Topical application of the composition can increase elastin expression, increase elastin secretion, or increase elastin fiber formation in the skin in need thereof, and the appearance of loose, sagging, or flaccid skin can be reduced.
BACKGROUND: Olfactory dysfunction is a common COVID-19 symptom, posing treatment challenges.
OBJECTIVES: We aimed to investigate the efficacy of frequency-controlled ear acupuncture in treating COVID-19-related olfactory dysfunction.
METHODS: A randomized, participant-blind clinical trial occurred at the Rasoul Akram Hospital (IRCT20210311050671N1). Forty patients were recruited, and 20 patients were randomly assigned to either the experimental or control group. The primary outcome was the improvement in patients' quality of smell. The olfactory dysfunction was confirmed using the Smell Identification Test. The intervention group received two sessions of acupuncture treatment according to auricular frequency treatment, with a one-week interval, while the control group received an equal number of switched-off laser sessions. Both groups were instructed to use nasal betamethasone drops. The patients were asked to rank their ability to smell before and after each intervention on a 10-point visual analog scale. Secondary outcomes were related side effects.
RESULTS: Covariance analysis revealed a significant difference in adjusted scores between the groups (F [37, 1] = 37.463; p = 0.000, Eta2 = 0.503). The smell quality improved from 2.80 ± 1.76 to 5.22 ± 3.40 after treatment in the intervention group (p = 0.007), while the control group showed no significant change (p = 0.184). Three patients reported short and transient side effects, such as nausea, headache, and dizziness, in the first hours after the intervention.
CONCLUSION: Frequency-controlled ear acupuncture is an effective option for treating COVID-19-related olfactory dysfunction. The study highlights the potential of alternative therapies in the treatment of this condition, and further research is warranted to investigate its long-term effects.
FIELD: biotechnology, agriculture. SUBSTANCE: invention uses the strain of E. coli preliminary transformed with recombinant vector. Vector has DNA fragment encoding swine growth hormone with N-terminal alanine pGH(A). This fragment is inserted after translation initiation site directly presented as methionine codon. Polypeptide pGH(A) no containing methionine at N-end is obtained without additional treatment. EFFECT: enhanced effectiveness. 8 dwg , 2 tbl
Bone injuries represent an important world medical problem producing significant healthcare and societal expenditure. While most bone injuries are not severe and are capable of healing through bone regeneration by natural callus formation with standard treatments, severe bone injuries may not heal, becoming an important unmet clinical need.

Non-unions, or pseudarthrosis, may occur in 5% to 20% of long-bone fractures that fail to heal properly after more than 6 months, with morbidity, prolonged hospitalization, and increased expenses. The most commonly accepted standard augmentation to procure fracture and non-union healing consists of autologous bone grafting, obtained from the same patient in a different surgical site and transplanted to the reconstruction site. However, autologous bone grafting has some drawbacks (such as persistent pain, scar, late recovery, limited amount of bone, etc) and a limited regeneration efficacy (success rate of about 74%) and high societal cost. Culture-expanded autologous MSCs combined with biphasic calcium phosphate (BCP) biomaterial granules have been claimed as a solid regenerative medicine alternative to autologous bone grafting in non-unions, although current data are limited. In this context, the ORTHOUNION initiative focuses on the opportunity to test the hypothesis of superiority of MSC, the investigational ATMP, versus the currently accepted standard therapy, iliac crest bone autograft to biologically augment surgical treatment of long-bone non-unions.
<P>PROBLEM TO BE SOLVED: To obtain a new bleaching ingredient having high effectiveness and an external preparation for skin for bleaching containing the same.  <P>SOLUTION: The bleaching ingredient comprises at least one kind selected from spiraeoside and kaempferol-7-neohesperidoside. The external preparation for skin for bleaching contains the bleaching ingredient. The bleaching ingredient has inhibitory action on tyrosinase activity, melanin production inhibition, inhibitory action on pigmentation, ameliorating action on human skin color and excellent bleaching effect. The external preparation for skin for bleaching, containing the bleaching ingredient, prevents or ameliorates stains, freckles, drabness and pigmentation such as skin blacking, etc., by suntan.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
1,138,313. Corticoid complexes. C. E. VERMEHREN, and T. L. M. VERMEHREN. 6 April, 1966 [9 April, 1965], No. 15367/66. Heading C2U. The invention comprises a water-soluble corticoid compound which decomposes substantially instantaneously in plasma or tissue fluid with liberation of the corticoid in free form which consists of the reaction product of (a) a mono-alkali metal or mono-ammonium salt of di-hydrocortisone 21-phosphate or di-prednisolone-21-phosphate and (b) a free 21-hydroxy corticoid, and its preparation by reaction of an aqueous solution of the phosphate salt with a solution of the free corticoid in a solvent at least partially miscible in water. The product is preferably converted to a homogeneous solid by freeze-drying. The compounds of the invention may be used to treat shock-like conditions by use dissolved in a carrier in injectable form.
This is a Phase I/II trial designed to evaluate the combination of the immunotherapeutic agent indoximod and the standard of care chemotherapy gemcitabine plus nab-paclitaxel in subjects with metastatic adenocarcinoma of the pancreas. The phase 1 portion is designed to identify the regimen-limiting toxicity (RLT) and recommended phase 2 dose (RP2D) for the combination. The phase 2 portion of the study will evaluate the potential efficacy of this combination. All subjects will receive the standard 28-day gemcitabine plus nab-paclitaxel regimen. Twice daily oral indoximod will be administered concurrently in continuous 28 day cycles.

In the phase 1 portion, dose escalation of indoximod will begin at 600 mg twice a day and potentially escalate to 1200 mg twice a day. There will be no intra-subject dose escalation. Regimen-limiting toxicity will be considered as those toxicities related to indoximod that significantly limit the administration of the backbone chemotherapy gemcitabine plus nab-paclitaxel. The period for determination of dose-limiting toxicities will be the initial 28 days of treatment. The recommended phase 2 dose will include an assessment of toxicities that occur at later time points.

Once a RP2D is determined, the phase 2 portion of the study will be initiated. In both phase 1 and phase 2, every 2 cycles subjects will have repeat imaging to assess response. Corollary biomarkers will be assessed at the same interval as will PET-CT after the 1st 8 week cycle. Up to 18 patients will be enrolled in the phase 1 portion of the study and 80 patients will be enrolled in the phase 2 portion.
Patients were eligible if they were aged 18 years or older, referred for HSCT and admitted to the Bone Marrow Transplant Unit (BMTU). Patients were screened in the BMTU admission and recruited to the study after avaliation in the first-day internation.
Three-dimensional structured illumination microscopy (3D-SIM) and fluorescence in situ hybridization on three-dimensional preserved cells (3D-FISH) have proven to be robust and efficient methodologies for analyzing nuclear architecture and profiling the genome's topological features. These methods have allowed the simultaneous visualization and evaluation of several target structures at super-resolution. In this chapter, we focus on the application of 3D-SIM for the visualization of 3D-FISH preparations of chromosomes in interphase, known as Chromosome Territories (CTs). We provide a workflow and detailed guidelines for sample preparation, image acquisition, and image analysis to obtain quantitative measurements for profiling chromosome topological features. In parallel, we address a practical example of these protocols in the profiling of CTs 9 and 22 involved in the translocation t(9;22) in Chronic Myeloid Leukemia (CML). The profiling of chromosome topological features described in this chapter allowed us to characterize a large-scale topological disruption of CTs 9 and 22 that correlates directly with patients' response to treatment and as a possible potential change in the inheritance systems. These findings open new insights into how the genome structure is associated with the response to cancer treatments, highlighting the importance of microscopy in analyzing the topological features of the genome.
Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (\> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).
Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness (AHR), inflammation, and remodeling. Epithelial-mesenchymal transition (EMT) is an essential player in these alterations. Scutellarin is isolated from Erigeron breviscapus. Its vascular relaxative, myocardial protective, and anti-inflammatory effects have been well established. This study was designed to detect the biological roles of scutellarin in asthma and its related mechanisms. The asthma-like conditions were induced by ovalbumin challenges. The airway resistance and dynamic compliance were recorded as the results of AHR. Bronchoalveolar lavage fluid (BALF) was collected and processed for differential cell counting. Hematoxylin and eosin staining, periodic acid-Schiff staining, and Masson staining were conducted to examine histopathological changes. The levels of asthma-related cytokines were measured by enzyme-linked immunosorbent assay. For in vitro analysis, the 16HBE cells were stimulated with 10 ng/mL transforming growth beta-1 (TGF-β1). Cell migration was estimated by Transwell assays and wound healing assays. E-cadherin, N-cadherin, and α-smooth muscle actin (α-SMA) were analyzed by western blotting, real-time quantitative polymerase chain reaction, immunofluorescence staining, and immunohistochemistry staining. The underlying mechanisms of the mitogen-activated protein kinase (MAPK) and Smad pathways were investigated by western blotting. In an ovalbumin-induced asthmatic mouse model, scutellarin suppressed inflammation and inflammatory cell infiltration into the lungs and attenuated AHR and airway remodeling. Additionally, scutellarin inhibited airway EMT (upregulated E-cadherin level and downregulated N-cadherin and α-SMA) in ovalbumin-challenged asthmatic mice. For in vitro analysis, scutellarin prevented the TGF-β1-induced migration and EMT in 16HBE cells. Mechanistically, scutellarin inhibits the phosphorylation of Smad2, Smad3, ERK, JNK, and p38 in vitro and in vivo. In conclusion, scutellarin can inactivate the Smad/MAPK pathways to suppress the TGF-β1-stimulated epithelial fibrosis and EMT and relieve airway inflammation and remodeling in asthma. This study provides a potential therapeutic strategy for asthma.
An improved, cost effective and shortened process of purification of the capsular polysaccharide of  S. Pneumoniae , Group B  Streptococcus, H. Influenzae, S. Typhoid  and  N. meningitidis  is disclosed. The process includes a cocktail of enzyme treatment, tangential flow filtration, and multimodal chromatography purification. For Gram-negative bacteria, endotoxin removal process involves endotrap HD resin. This shortened process achieved the purity required by WHO/EP/BP for the use in human vaccine preparation, with simple steps and higher yield as compared to conventional processes. The steps of the process avoid use of organic solvents such as, for example, alcohol, phenol, and ultracentrifugation that are otherwise expensive and time consuming to perform, and/or health hazards for commercial use. This process disclosed is also simple, efficient, non-toxic, easy to scale-up, and environmentally friendly.